Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors
Conditions
Brief summary
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Detailed description
This is a Phase 1/2 open-label study to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting. The study has 2 parts: Phase 1, Dose Escalation and Expansion, and Phase 2. Potential participants will provide written consent and be screened for study eligibility prior to undergoing any screening procedures, including leukapheresis. Protocol-specified criteria must be met prior to the start of leukapheresis for collection of peripheral blood mononuclear cells (PBMCs). Eligible participants will undergo leukapheresis to collect PBMCs for product manufacturing, which comprises enrichment of T cells, lentiviral transduction, ex vivo expansion, and cryopreservation of the CHM-2101 cell product. Participants who have a leukapheresis or manufacturing failure may be permitted a second attempt at leukapheresis. Bridging chemotherapy (treatment between the time of leukapheresis and first dose of lymphodepleting chemotherapy \[LDC\]) is permitted at the discretion of the investigator, if needed to maintain disease stability during CHM-2101 manufacturing time. Bridging chemotherapy is prohibited within the 2 weeks prior to leukapheresis and 2 weeks prior to planned CHM-2101 infusion. Specific criteria to proceed should be reviewed prior to leukapheresis, LDC, and CHM-2101 infusion. Participants will be followed in this study for 18 months or until disease progression.
Interventions
BIOLOGICALCHM-2101 CAR-T cells
Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
Sponsors
Chimeric Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Documented informed consent of the participant and/or legally authorized representative. 2. Confirmed histologic diagnosis of one of the following solid tumors of GI origin: 1. Gastric adenocarcinoma Note: for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required. 2. Colon and/or rectal adenocarcinoma 3. G1, G2, and well-differentiated G3 neuroendocrine tumors of the midgut and hindgut (ileal, jejunal, cecal, distal colonic, or rectal; with ≤ 55% Ki67 expression) 3. Availability of unstained tumor tissue slides from archived tumor tissue or a new tumor biopsy, if medically feasible. Note: for gastric adenocarcinoma patients only, confirmation of CDH17+ is required prior to study inclusion. 4. Have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting, as defined by National Comprehensive Cancer Network (NCCN) guidelines. Participants must have received or declined FDA-approved and available treatment options, including targeted therapies for disease mutation or antigen expression status. 5. Age ≥ 18 years and ≤ 85 years. 6. For Phase 1 Dose Expansion and Phase 2 only: Measurable disease as per RECIST v1.1 criteria (Note: Measurable disease is NOT required for Phase 1 Dose Escalation). 7. Eastern Cooperative Oncology Group (ECOG) ≤ 1. 8. Life expectancy ≥ 12 weeks. 9. No known contraindications to leukapheresis, cyclophosphamide, fludarabine, or steroids. 10. Baseline laboratory values as shown in the following table: Minimum Laboratory Values for Study Entry Laboratory Assessment Criteria White blood cell count \> 4,000/mm3 Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate amino transferase (AST) ≤ 3 x ULN Alanine transaminase (ALT) ≤ 3 x ULN Creatinine clearance by Cockroft-Gault equation 60 mL/min Oxygen saturation ≥ 92% on room air Albumin ≥ 3 g/dL 11. Left ventricular ejection fraction ≥ 50%. 12. Seronegative for human immunodeficiency virus (HIV) by antigen/antibody (Ag/Ab) testing. 13. Seronegative for hepatitis B and/or hepatitis C virus. 14. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. 15. Agreement by women and men of childbearing potential to use an effective method of birth control or abstain from heterosexual activity through at least 3 months after the last dose of CHM-2101.
Exclusion criteria
1. Previous treatment with CDH17-targeted therapies. 2. Unresolved toxicities from prior therapy except for chronic toxicity no greater than Grade 1 and stable \> 30 days (Note: alopecia of any grade is not exclusionary). 3. Uncontrolled seizure activity and/or known central nervous system (CNS) metastases. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent. 5. Uncontrolled Crohn's disease, ulcerative colitis, or other autoimmune or inflammatory disorders of the GI tract. "Uncontrolled" is defined as requiring hospitalization, corticosteroids, or chronic medication increase (dosage or frequency) within the previous 6 months. 6. Liver involvement ≥ 50%. 7. Active infection requiring oral or IV antibiotics. 8. Current diagnosis of pleural effusions, interstitial lung disease, or heart failure of New York Heart Association Classification of Heart Failure Class III or IV. 9. Ongoing treatment with systemic corticosteroid therapy at doses of prednisone ≥ 20 mg/day or equivalent (lower doses of corticosteroid therapy are allowed until 7 days prior to leukapheresis). 10. No prior malignancy within 5 years except for non-melanomatous skin cancer or cervical cancer treated with curative intent 11. Currently breastfeeding or planning to become pregnant within 9 months of study enrollment. 12. Any other clinically significant uncontrolled illness or other comorbid condition that would, in the investigator's judgment, contraindicate the participant's participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Limiting Toxicity (DLT) | 28 Days | Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
| Rates and Grades of Cytokine Release Syndrome (CRS) | up to 15 years | Assessed per American Society for Transplant and Cellular Therapy (ASTCT) consensus grading guideline |
| All other adverse events and toxicities | up to 15 years | Assessed per NCI CTCAE v5.0 |
| Objective Response Rate (ORR) | up to 15 years | Assessed by RECIST v 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | up to 15 years | Assessed as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease to a therapeutic intervention in clinical trials of anticancer agents. |
| Time to response (TTR) | up to 15 years | Measured as the amount of time elapsed until drug response is achieved for the first time. |
| Duration of response (DOR) | up to 15 years | Measured as the amount of time a patient responds to a treatment before disease progresses or the patient dies. |
| Progression-free survival (PFS) | up to 15 years | Measured from the date of first infusion of CAR-T cells until the first date when progressive disease (PD) is objectively documented or death from any cause, whichever is earlier. |
| Overall survival (OS) | up to 15 years | Measured from the date of first infusion of CAR-T cells until death. |
Countries
United States
Contacts
CONTACTChimeric Clinical
PRINCIPAL_INVESTIGATORJennifer Eads, MD
University of Pennsylvania
Outcome results
None listed